



US00RE46276E

(19) **United States**
(12) **Reissued Patent**
Hardem et al.

(10) **Patent Number:** **US RE46,276 E**
(45) **Date of Reissued Patent:** **Jan. 17, 2017**

(54) **TRIAZOLO(4,5-D)PYRIMIDINE
COMPOUNDS**

(71) Applicant: **AstraZeneca UK Limited**, London
(GB)

(72) Inventors: **David Hardem**, Sutton Bonington
(GB); **Anthony Ingall**, Minehead (GB);
Brian Springthorpe, Stanford on Soar
(GB); **Paul Willis**, Geneva (CH);
Simon Guile, Hathern (GB)

(73) Assignee: **AstraZeneca UK Limited**, London
(GB)

(21) Appl. No.: **14/976,977**

(22) Filed: **Dec. 21, 2015**

Related U.S. Patent Documents

Reissue of:

(64) Patent No.: **6,525,060**
Issued: **Feb. 25, 2003**
Appl. No.: **09/508,195**
PCT Filed: **Dec. 2, 1999**
PCT No.: **PCT/SE99/02256**
§ 371 (c)(1),
(2) Date: **Mar. 8, 2000**
PCT Pub. No.: **WO00/34283**
PCT Pub. Date: **Jun. 15, 2000**

(30) Foreign Application Priority Data

Dec. 4, 1998 (SE) 9804211
Apr. 9, 1999 (SE) 9901271

(51) Int. Cl.

C07D 239/00 (2006.01)
A61K 31/519 (2006.01)
A61P 9/00 (2006.01)
A61P 9/10 (2006.01)
C07D 239/48 (2006.01)
C07D 487/04 (2006.01)
C07D 487/00 (2006.01)
C07C 211/40 (2006.01)

(52) U.S. Cl.

CPC **C07D 487/04** (2013.01); **A61K 31/519**
(2013.01); **C07C 211/40** (2013.01); **C07D**
239/48 (2013.01)

(58) Field of Classification Search

None
See application file for complete search history.

(56) References Cited

U.S. PATENT DOCUMENTS

3,106,578 A 10/1963 Kaiser et al.
3,509,129 A 4/1970 Kampe et al.
3,590,029 A 6/1971 Koch et al.
4,016,204 A 4/1977 Rajadhyaksha
4,543,255 A 9/1985 Shealy et al.
4,742,064 A 5/1988 Vince
5,288,726 A 2/1994 Koike et al.
5,338,725 A 8/1994 Ojima et al.
5,620,676 A 4/1997 Jacobson et al. 514/263

5,631,259 A 5/1997 Jahne et al.
5,652,366 A 7/1997 Spada et al.
5,688,774 A 11/1997 Jacobson et al.
5,747,496 A 5/1998 Cox et al.
5,817,660 A 10/1998 Borchering et al.
5,831,099 A 11/1998 Dave et al.
5,948,437 A 9/1999 Parikh et al.
5,997,089 A 12/1999 Kawasaki
6,156,756 A 12/2000 Hardem et al.
6,251,910 B1 6/2001 Guile et al. 514/258
6,559,143 B1 5/2003 Bjore et al.
6,605,600 B1 8/2003 Ensinger et al.
6,974,868 B2 12/2005 Hardem et al.
7,250,419 B2 7/2007 Hardem et al.
7,265,124 B2 9/2007 Bohlin et al.
8,425,934 B2 4/2013 Banks
9,056,838 B2 6/2015 Kansal et al.
9,359,366 B2 6/2016 Sun et al.
2003/0165563 A1 9/2003 Murphy et al.
2007/0265282 A1 11/2007 Hardem et al.
2008/0214812 A1 9/2008 Hardem et al.
2010/0069408 A1 3/2010 Hardem et al.
2012/0165348 A1 6/2012 Hardem et al.
2013/0072503 A1 3/2013 Hardem et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CA 994773 A 8/1976
EP 0 521 463 A2 1/1993

(Continued)

OTHER PUBLICATIONS

Paragraph IV Certification Letter #1, dated Oct. 1, 2015, pp. 1-34.
Paragraph IV Certification Letter #2, dated Sep. 23, 2015, pp. 1-50.
Paragraph IV Certification Letter #3, dated Sep. 18, 2015, pp. 1-72.
Paragraph IV Certification Letter #4, dated Sep. 17, 2015, pp. 1-145.
Paragraph IV Certification Letter #5, dated Oct. 5, 2015, pp. 1-67.
Paragraph IV Certification Letter #6, dated Oct. 3, 2015, pp. 1-58
and Appendix pp. 1-8.


Daly et al., Structure-Activity Relationships for N6-Substituted
Adenosines at a Brain A1-Adenosine Receptor with a Comparison
to an A2-Adenosine Receptor Regulating Coronary Blood Flow,
Biochemical Pharmacology 35:2467-81 (1986).

(Continued)

Primary Examiner — Alan Diamond

(57) ABSTRACT

Triazolo[4,5-d]pyrimidine compounds, their use as medica-
ments, compositions containing them and processes for their
preparation. The compounds of the invention have the
formula (I) as follows:



wherein R, X and R¹ through R³ are as defined in the
specification.

23 Claims, No Drawings